LPA and liver disorder: We will also summarize evidence on pathological conditions that modify Lp(a) levels, including kidney and liver diseases, emphasizing the magnitude and directionality of their effects as pertinent to cardiovascular risk as well as the apo(a) size polymorphism (for a summary, see Box 1).